INCY
Closed
Incyte Corporation
68.73
+0.63 (+0.93%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 68.1
Day's Range: 66.83 - 70.37
Send
sign up or login to leave a comment!
When Written:
72.4
Incyte Corporation is a biopharmaceutical company that is headquartered in Wilmington, Delaware. The company was founded in 1991 and focuses on the discovery, development, and commercialization of drugs for the treatment of cancer and other diseases.
Incyte's flagship product is Jakafi (ruxolitinib), which is used to treat patients with myelofibrosis, a rare blood cancer. The company also has a number of other drugs in development, including treatments for solid tumors, autoimmune diseases, and bone marrow disorders.
Incyte has a strong research and development program and collaborations with other pharmaceutical companies and academic institutions. The company has partnerships with Novartis, Merus, and MorphoSys, among others.
Incyte is publicly traded on the NASDAQ stock exchange under the ticker symbol INCY. The company has a market capitalization of over $20 billion and employs over 1,500 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Incyte's flagship product is Jakafi (ruxolitinib), which is used to treat patients with myelofibrosis, a rare blood cancer. The company also has a number of other drugs in development, including treatments for solid tumors, autoimmune diseases, and bone marrow disorders.
Incyte has a strong research and development program and collaborations with other pharmaceutical companies and academic institutions. The company has partnerships with Novartis, Merus, and MorphoSys, among others.
Incyte is publicly traded on the NASDAQ stock exchange under the ticker symbol INCY. The company has a market capitalization of over $20 billion and employs over 1,500 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








